MI-mAbs - Antibodies for medicine


MI-mAbs is the French demonstrator of immunotherapy antibodies. By converting the most promising targets from academia, start-ups and industry into drug candidates and developing cutting-edge immunotechnologies, MI-mAbs allows research institutions, public technology transfer offices and biotech companies to de-risk the development of next generation immunotherapies against cancer and inflammatory diseases, keeping one step ahead of the competition.

Located in the historical birthplace of Marseille Immunopôle, the MI-mAbs’ building homes a fully integrated suite of platforms covering all steps leading to preclinical proof-of-concept. All R&D projects are managed in an industrial mindset by a multi-disciplinary team of experts specifically dedicated to antibody engineering, biochemistry, immunohistochemistry, bioproduction and immunopharmacology. MI-mAbs has also established and continues to set up strategic scientific and technological partnerships both with academia and industry, notably with CIPHE (Transgenic mouse model engineering and  immunomonitoring), the IPC (human tissues), the CRCM (llama technology)…

Prize-Winner of the program “Investments for the Future” in the "pre-industrial demonstrators" category », MI-mAbs was founded in 2011 by Aix-Marseille University (AMU) and its subsidiary Protisvalor, the CNRS, the Inserm, the Institut Paoli-Calmettes (IPC), the French leader in Immuno-Oncology, Innate Pharma and one of the world's leaders in healthcare, Sanofi; AMU and Protisvalor ensure its administration. MI-mAbs is a founding member of the French immunology cluster Marseille Immunopôle.